Skip to Content
Merck
  • Efficient iron utilization compensates for loss of extracellular matrix of ovarian cancer spheroids.

Efficient iron utilization compensates for loss of extracellular matrix of ovarian cancer spheroids.

Free radical biology & medicine (2021-01-16)
Qian Wang, Tingting Gu, Li Ma, Shixia Bu, Wenjing Zhou, Guoping Mao, Lu-Lu Wang, Ying Guo, Dongmei Lai
ABSTRACT

Metastasis is the major cause of death in women with advanced ovarian cancer. Epithelial ovarian cancer cells can dissociate directly from extracellular matrix (ECM) and form spheroids to spread through the peritoneal cavity. Loss of ECM hinders the survival of ECM-detached epithelial cells. It is still largely unknown how ovarian cancer spheroids maintain their viability after loss of ECM. We find that spheroids derived either from ovarian cancer ascites or cell lines are iron-replete. In accordance with iron-replete condition, proteins involved in iron uptake, transport and storage including divalent metal ion transporter 1 (DMT1), transferrin receptor 1 (TFR1), ferritin, poly(rC)-binding proteins 1 and 2 (PCBP1 and 2) and nuclear factor E2-related factor 2 (NRF2) all increase in ovarian cancer spheroids. Genes linking iron homeostasis and lipid metabolism including stearoyl coenzyme A desaturase 1 (SCD1) are up-regulated in ovarian cancer spheroids. The product of SCD1 oleic acid can restore the viability of ovarian cancer spheroids inhibited by deprivation of iron. Extracellular signal-regulated kinase (ERK) activation contributes to autophagy activation in ovarian cancer spheroids. Impairment of autophagy by U0126 or Olaparib results in lysosomal iron accumulation and decrease of the cytosolic labile iron pool, leading to reduction of SCD1, lipid level and cell viability. Combination of U0126 and Olaparib has synergistic cytotoxicity toward ovarian cancer spheroids. Our findings reveal that ovarian cancer spheroids develop efficient iron utilization system to survive. Targeting iron utilization in ovarian cancer spheroids may have the potential to become new treatment strategies for ovarian cancer metastasis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Deferoxamine mesylate salt, powder, ≥92.5% (TLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, 98%
Sigma-Aldrich
Ferric citrate, BioReagent, suitable for cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human RB1CC1
Supelco
Bathophenanthroline, for spectrophotometric det. of Fe in serum, ≥99.0%